Investing.comCodex · 实盘不做把握 8/10
北京时间·🕒 发布 13:04:39时区推断·⟳ 抓取 13:05:16·⚡ 决策 08-04 13:12:42 +7m26s·84.2 天前
Nurix与Roche合作的bexobrutideg注册性3期CLL/SLL试验首例患者入组
bexobrutideg首次进入全球3期DAYBreak CLL-306并计划入组约620名复发或难治CLL/SLL患者，属研发里程碑。
📄 原文Investing.com↗ 原文
Nurix enrolls first patient in phase 3 trial for CLL drug
Dow posts first record close in nearly a month as stocks rally to kick off August BRISBANE, Calif. - Nurix Therapeutics…
不做 Nurix Therapeutics（NRIX.US）
同一bexobrutideg注册性3期首例患者入组催化已在05:04/05:06 UTC处理；当前为重复转述，不再出卡。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-04 · 扩散 medium · price-in 风险 high ↗
关键理由
- bexobrutideg首次进入全球3期DAYBreak CLL-306并计划入组约620名复发或难治CLL/SLL患者，属研发里程碑。
- 已处理消息库在同窗口已有Nurix同一首例患者入组催化记录，当前为重复转述；按去重纪律不再出卡。
主要风险
- 首例患者入组距离读出和监管申报仍远，且本条不是新增疗效或商业化数据。
工具调用 · 历史记录,结果未知(2 种)
- search_processed_events · 结果未知
- normalize_ticker · 结果未知
原文全文
展开原文 · 2,141 字
Dow posts first record close in nearly a month as stocks rally to kick off August
BRISBANE, Calif. - Nurix Therapeutics Inc. (NASDAQ:NRIX) enrolled the first patient in its global Phase 3 DAYBreak CLL-306 study evaluating bexobrutideg in patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma who previously received a covalent BTK inhibitor, according to a press release statement issued today.
The study, identified as NCT07516093, marks the first Phase 3 trial for bexobrutideg, a targeted protein degrader of Bruton’s tyrosine kinase. Nurix is conducting the trial in collaboration with Roche.
The randomized trial will enroll approximately 620 patients with relapsed or refractory CLL/SLL who previously progressed on a covalent BTK inhibitor. Patients will be randomized 1:1 to receive either bexobrutideg 600 mg orally once per day or pirtobrutinib. The dual primary endpoints are objective response rate and progression free survival, as assessed by an independent review committee.
The study is designed to evaluate the potential superiority of bexobrutideg relative to pirtobrutinib and support global regulatory submissions.
"This is an important milestone for the global bexobrutideg development program with the potential to redefine the treatment landscape for patients with CLL through a head-to-head comparison of BTK degradation versus non-covalent inhibition," said Arthur T. Sands, president and chief executive officer of Nurix.
Bexobrutideg is currently being evaluated in multiple clinical trials including the DAYBreak CLL-201 Phase 2 study in patients with relapsed or refractory CLL, and the NX-5948-301 Phase 1a/1b trial in patients with relapsed or refractory B-cell malignancies. A tablet formulation is being evaluated in healthy volunteers to support future development in immunology and neurology indications.
Nurix is a clinical stage biopharmaceutical company focused on targeted protein degradation medicines and is headquartered in Brisbane, California.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
BRISBANE, Calif. - Nurix Therapeutics Inc. (NASDAQ:NRIX) enrolled the first patient in its global Phase 3 DAYBreak CLL-306 study evaluating bexobrutideg in patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma who previously received a covalent BTK inhibitor, according to a press release statement issued today.
The study, identified as NCT07516093, marks the first Phase 3 trial for bexobrutideg, a targeted protein degrader of Bruton’s tyrosine kinase. Nurix is conducting the trial in collaboration with Roche.
The randomized trial will enroll approximately 620 patients with relapsed or refractory CLL/SLL who previously progressed on a covalent BTK inhibitor. Patients will be randomized 1:1 to receive either bexobrutideg 600 mg orally once per day or pirtobrutinib. The dual primary endpoints are objective response rate and progression free survival, as assessed by an independent review committee.
The study is designed to evaluate the potential superiority of bexobrutideg relative to pirtobrutinib and support global regulatory submissions.
"This is an important milestone for the global bexobrutideg development program with the potential to redefine the treatment landscape for patients with CLL through a head-to-head comparison of BTK degradation versus non-covalent inhibition," said Arthur T. Sands, president and chief executive officer of Nurix.
Bexobrutideg is currently being evaluated in multiple clinical trials including the DAYBreak CLL-201 Phase 2 study in patients with relapsed or refractory CLL, and the NX-5948-301 Phase 1a/1b trial in patients with relapsed or refractory B-cell malignancies. A tablet formulation is being evaluated in healthy volunteers to support future development in immunology and neurology indications.
Nurix is a clinical stage biopharmaceutical company focused on targeted protein degradation medicines and is headquartered in Brisbane, California.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。